Welcome to the Erickson-Huber Fragile X Center

Our goals are (truncated specific aims)
    1. Purpose: The primary aim of the Erickson-Huber Fragile X Center is to advance scientific knowledge about Fragile X syndrome and related disorders, as well as to improve the lives of individuals and families affected by these conditions. The center achieves this through research, clinical care, education, and advocacy.
    2. Goals: The Erickson-Huber Fragile X Center has several specific goals, including:
    • Conducting innovative research to better understand the causes and underlying mechanisms of Fragile X syndrome and related disorders.
    • Developing new and improved diagnostic and treatment strategies for these conditions.
    • Providing high-quality clinical care to individuals affected by Fragile X syndrome and related disorders, with a focus on addressing the diverse needs of patients and their families.
    • Offering education and training opportunities for healthcare professionals, researchers, and students who are interested in Fragile X syndrome and related disorders.
    • Advocating for policies and programs that support individuals and families affected by Fragile X syndrome and related disorders and promoting public awareness of these conditions.

These are our people (bios separated by site)
CCHMC / UC: https://www.cincinnatichildrens.org/research/divisions/p/psychiatry/labs/erickson-wink 

    • Craig Erickson (https://www.cincinnatichildrens.org/bio/e/craig-erickson): 
        ◦ Dr. Craig Erickson, MD, is a highly regarded psychiatrist and internationally renowned expert in Fragile X syndrome who currently works at Cincinnati Children's Hospital Medical Center. He has received continuous funding to support his research in translational treatment development for neurodevelopmental disorders, and he is an expert in the clinical treatment and trial development of Fragile X syndrome. Dr. Erickson has also patented several treatments and is known for moving forward repurposed and novel molecules for study in Fragile X syndrome and autism spectrum disorder.


    • Ernest Pedapati (https://www.cincinnatichildrens.org/bio/p/ernest-pedapati): 
        ◦ Dr. Ernest Pedapati, MD, MS, FAAP, is a specialist in treating neuropsychiatric diseases associated with neurodevelopmental disorders, including Fragile X syndrome and autism spectrum disorder, and has advanced training in medication management. He completed a study on cortical plasticity in adolescent depression using TMS after receiving funding through a competitive award, and he has also conducted research on TMS measures of cortical plasticity in ASD and motor physiology in ADHD. He received a mentor career development award during his residency to support his independent research activities and was recently awarded a grant to study neuromodulation of brain activity associated with language development.


    • Lauren Schmitt (https://www.cincinnatichildrens.org/bio/s/lauren-schmitt):
        ◦ Dr. Lauren Schmitt, PhD, is a clinical psychologist specializing in diagnostic and behavioral intervention services for individuals with neurodevelopmental disabilities, particularly autism spectrum disorder, and is currently employed at Cincinnati Children's Hospital Medical Center. Her primary area of research involves cognitive flexibility, response inhibition, and speech production, with a focus on establishing clinical biomarkers of sensorimotor and cognitive deficits in ASD and Fragile X syndrome. Dr. Schmitt has also been involved in clinical drug trials, using electroencephalogram (EEG) and clinical data to differentiate responders from non-responders in FXS.
        ◦ 

    • John Sweeney (https://med.uc.edu/depart/psychiatry/directory/faculty-profile/Index/Pubs/sweenej5):
        ◦ Dr. John Sweeney, PhD, is a professor of psychiatry and behavioral neuroscience at the University of Cincinnati. He is also the director of the UC Center for Imaging Research, which focuses on using advanced imaging techniques to study brain function and its relationship to mental illness. Dr. Sweeney's research interests include Fragile X syndrome, schizophrenia, bipolar disorder, and autism spectrum disorder, with a particular focus on using brain imaging to better understand the neural mechanisms underlying these conditions.


    • Christina Gross (https://www.cincinnatichildrens.org/bio/g/christina-gross):
        ◦ Dr. Nina Gross, PhD, is a neuroscientist at Cincinnati Children’s Hospital Medical Center who has a passion for understanding how the brain works and how it is affected by disorders such as Fragile X syndrome, autism, and epilepsy. Her lab focuses on identifying molecular mechanisms that contribute to these disorders and how they affect brain function. She has received funding from the National Institutes of Health (NIH) and other organizations for her work, including identifying potential novel brain treatments.

    • Rebecca Schaffer (https://www.cincinnatichildrens.org/bio/s/rebecca-shaffer):
        ◦ Dr. Rebecca Shaffer, PsyD, is a clinical psychologist and researcher at Cincinnati Children’s Hospital Medical Center who is dedicated to treating and researching neurobehavioral disorders. Her focus is on emotional regulation in children with disorders such as autism spectrum disorder, Fragile X syndrome, and Angelman syndrome. She leads a treatment program called Regulating Together, which treats emotion dysregulation in children with ASD in a group setting with concurrent caregiver training. Dr. Shaffer is committed to training future leaders in neurobehavioral care and has overseen several Fragile X research studies.
OU: https://ouhsc.edu/bbmc/babl/ 

    • Lauren Ethridge (https://medicine.ouhsc.edu/academic-departments/pediatrics/sections/developmental-behavioral-pediatrics/faculty/lauren-e-ethridge-phd):
        ◦ Dr. Lauren Ethridge, PhD, is an associate professor of psychology at the University of Oklahoma. She received her PhD in neuroscience from the University of Georgia and completed her postdoctoral training at the Center for Autism and Developmental Disabilities at UT Southwestern Medical Center. Dr. Ethridge's research focuses on the use of dense-array EEG to establish non-invasive biological markers for changes in brain function related to neurodevelopmental disorders, such as Fragile X syndrome and autism spectrum disorder. The ultimate goal of her research is to aid in early identification, prediction of treatment response, and assessment of treatment effects.
UTSW: https://labs.utsouthwestern.edu/huber-lab 

    • Kim Huber (https://profiles.utsouthwestern.edu/profile/50231/kimberly-huber.html):
        ◦ Dr. Kimberly Huber, PhD, is a neurobiologist and professor at UT Southwestern who received her PhD in Neurobiology from The University of Texas Graduate School of Biomedical Sciences. Her research is focused on understanding the mechanisms of synapse and neural circuit development and plasticity, particularly in relation to Fragile X syndrome and autism. Her lab utilizes advanced techniques in neurophysiology, imaging, biochemistry, and molecular biology to discover novel molecular mechanisms of synaptic plasticity and new functions for the FMR1 gene. Her work has led to a better understanding of neurobiology and identified new therapeutic strategies.

    • Jay Gibson (https://profiles.utsouthwestern.edu/profile/50230/jay-gibson.html):
        ◦ Dr. Jay Gibson, PhD, is a neuroscientist and researcher at UT Southwestern. He completed his undergraduate degree in biophysics at UC Berkeley and earned his PhD from the University of Rochester, where he studied neocortical activity related to visual processing. He joined the Center for Basic Neuroscience at UT Southwestern in 2001 and now focuses on using electrophysiological techniques to study cortical inhibitory circuitry plasticity and alterations in circuitry in the Fragile X syndrome mouse model.

UCR: https://www.binderlab.com/ 

    • Devin Binder (https://profiles.ucr.edu/app/home/profile/dbinder):
        ◦ Dr. Devin K. Binder, MD, PhD, is an associate professor in residence in the Department of Biomedical Sciences at the University of California, Riverside. He earned his MD and PhD degrees from Duke University, completed a residency in neurological surgery at the University of California, San Francisco, and undertook a neurosurgical and neuroscience fellowship at the University of Bonn. Dr. Binder is dedicated to teaching and has won awards for teaching at various institutions. He is affiliated with several organizations related to neuroscience and neurological surgery.

    • Khaleel Razak (https://profiles.ucr.edu/app/home/profile/khaleel):
        ◦ Dr. Khaleel Razak, PhD, is a professor of psychology at the University of California, Riverside. He obtained his PhD in behavioral neuroscience from the University of Texas at Austin and completed postdoctoral training at the University of California, San Francisco. Dr. Razak's research focuses on understanding the neural mechanisms underlying sensory processing and perception, particularly in the auditory system, using a combination of behavioral, electrophysiological, and imaging techniques in animal models. His work has contributed to a better understanding of how the brain processes complex sounds and how this process can be disrupted in various neurological disorders.
UIC: https://psch.uic.edu/ 

    • Mike Ragozzino (https://psch.uic.edu/profiles/ragozzino-michael/):
        ◦ Dr. Mike Ragozzino, PhD, is a professor of psychology at the University of Illinois at Urbana-Champaign. He received his PhD in experimental psychology from the University of Florida in 1993. Dr. Ragozzino's research focuses on the neural and cognitive mechanisms that underlie learning and memory processes, including how different brain regions interact to support these processes. His work has implications for understanding cognitive disorders such as Alzheimer's disease and for developing more effective treatments for cognitive deficits.

Here is our work (links to papers, preferably links that lead to "full-text" being available)
    • https://pubmed.ncbi.nlm.nih.gov/35379866/
        ◦ Boggs AE, Schmitt LM, McLane RD, Adayev T, LaFauci G, Horn PS, Dominick KC, Gross C, Erickson CA. Optimization, validation and initial clinical implications of a Luminex-based immunoassay for the quantification of Fragile X Protein from dried blood spots. Scientific reports. 2022 April 4;12(1):5617. PubMed PMID: 35379866; PubMed Central PMCID: PMC8980090; DOI: 10.1038/s41598-022-09633-8.
    • https://pubmed.ncbi.nlm.nih.gov/36167501/ 
        ◦ Jonak CR, Pedapati EV, Schmitt LM, Assad SA, Sandhu MS, DeStefano L, Ethridge L, Razak KA, Sweeney JA, Binder DK, Erickson CA. Baclofen-associated neurophysiologic target engagement across species in fragile X syndrome. Journal of neurodevelopmental disorders. 2022 September 27;14(1):52. PubMed PMID: 36167501; PubMed Central PMCID: PMC9513876; DOI: 10.1186/s11689-022-09455-9.
    • https://pubmed.ncbi.nlm.nih.gov/36494861/ 
        ◦ Schmitt LM, Li J, Liu R, Horn PS, Sweeney JA, Erickson CA, Pedapati EV. Altered frontal connectivity as a mechanism for executive function deficits in fragile X syndrome. Molecular autism. 2022 December 9;13(1):47. PubMed PMID: 36494861; PubMed Central PMCID: PMC9733336; DOI: 10.1186/s13229-022-00527-0.
    • https://pubmed.ncbi.nlm.nih.gov/36688132/ 
        ◦ Schmitt LM, Arzuaga AL, Dapore A, Duncan J, Patel M, Larson JR, Erickson CA, Sweeney JA, Ragozzino ME. Parallel learning and cognitive flexibility impairments between Fmr1 knockout mice and individuals with fragile X syndrome. Frontiers in behavioral neuroscience. 2022;16:1074682. PubMed PMID: 36688132; PubMed Central PMCID: PMC9849779; DOI: 10.3389/fnbeh.2022.1074682.
    • https://pubmed.ncbi.nlm.nih.gov/35820583/ 
        ◦ Ding L, Shou G, Cha YH, Sweeney JA, Yuan H. Brain-wide neural co-activations in resting human. NeuroImage. 2022 October 15;260:119461. PubMed PMID: 35820583; PubMed Central PMCID: PMC9472753; DOI: 10.1016/j.neuroimage.2022.119461.
    • https://pubmed.ncbi.nlm.nih.gov/35588990/ 
        ◦ Holley AJ, Shedd A, Boggs A, Lovelace J, Erickson C, Gross C, Jankovic M, Razak K, Huber K, Gibson JR. A sound-driven cortical phase-locking change in the Fmr1 KO mouse requires Fmr1 deletion in a subpopulation of brainstem neurons. Neurobiology of disease. 2022 August;170:105767. PubMed PMID: 35588990; PubMed Central PMCID: PMC9273231; DOI: 10.1016/j.nbd.2022.105767.
    • https://pubmed.ncbi.nlm.nih.gov/36411085/ 
        ◦ Norris JE, DeStefano LA, Schmitt LM, Pedapati EV, Erickson CA, Sweeney JA, Ethridge LE. Hemispheric Utilization of Alpha Oscillatory Dynamics as a Unique Biomarker of Neural Compensation in Females with Fragile X Syndrome. ACS chemical neuroscience. 2022 December 7;13(23):3389-3402. PubMed PMID: 36411085; DOI: 10.1021/acschemneuro.2c00404.

